Oct 2026· Anticancer Research· Vol 46, pp. 5879 - 5889· 0 citations· 35 references
Medicine
Abstract
Background/Aim: Immune-checkpoint blockade is most effective when tumor antigens are visible, innate sensing is intact, and effector lymphocytes can enter the tumor microenvironment. This narrative review evaluates regulated tumor-cell death as the mechanistic interface between chemotherapy and checkpoint inhibition. Materials and Methods: PubMed/MEDLINE and ClinicalTrials.gov were searched for English language records published from January 2005 through August 2026. Consensus definitions, mechanistic studies with functional immune endpoints, randomized phase III trials and mature updates, and longitudinal human translational studies were prioritized. Results: Immunogenic cell death is best considered a functional immunologic outcome of a dying-cell context rather than a death pathway equivalent to ferroptosis, necroptosis, or pyroptosis. Chemotherapy may promote antigen release, innate sensing, dendritic-cell activation, and T-cell priming, but it may also deplete immune effectors or provoke suppressive inflammation. Pivotal chemoimmunotherapy trials demonstrate clinical benefit in several cancers; however, efficacy does not establish that cell death was immunogenic or identify a specific death program. Ferroptosis, necroptosis, and pyroptosis remain predominantly preclinical in this setting. A dynamic biomarker framework should integrate proximal danger signals with antigen presentation, tumor-reactive T-cell expansion, and spatial immune remodeling. Conclusion: Regimen design should define the intended immune-conditioning window and verify adaptive priming with longitudinal tissue, blood, and imaging measurements. This approach may guide sequencing, de-escalation, and mechanism-based treatment changes when tumor shrinkage occurs without immune priming.
Radiotherapy can convert local tumor injury into systemic antitumor immunity, but this effect depends less on the nominal mode of cell death than on the tissue state that follows irradiation. This narrative review reframes radiation-induced regulated cell death around four functional outputs: antigen preservation, prod...
Xiao-Dong Wang, Wei Gao, Qian-Qian Wang et al.· Cancer Letters· 0 citations
Oncolytic viruses (OVs) are increasingly viewed not only as tumor-lysing agents but also as immunotherapeutic platforms capable of functioning as in situ cancer vaccines. By selectively infecting malignant cells, inducing immunogenic cell death, releasing tumor-associated antigens and danger signals, and activating inn...
Kamil Rogalski, Michał Iwaszko, Anna Kuraś et al.· Microorganisms· 0 citations
Tumor immunotherapy has demonstrated significant clinical value in various malignancies by activating the host antitumor immune response. However, its clinical benefits are still limited by factors such as insufficient tumor immunogenicity, an immunosuppressive tumor microenvironment (TME), and acquired drug resistance...
Rui-Jie Xu· Transactions on Materials, B...· 0 citations
Oncolytic viruses (OVs) preferentially infect and replicate within tumors, induce immunogenic cell death, and remodel immune-poor microenvironments to support T-cell infiltration. These features provide a rationale for combining OVs with immune checkpoint blockade, adoptive cellular therapies, bispecific T-cell engager...
Qing-Qing Wang, Jing Su, Yu Gao et al.· Frontiers in Immunology· 0 citations
This review focuses on targetable biomarker classes that link resistance biology to therapeutic sensitization across cancers, including transcription factors, genomic alterations, immune checkpoint proteins and metabolic regulators, and discusses the mechanistic basis of resistance-associated biomarkers.
Chao Wang, Dong Yang· Frontiers in Cell and Develo...· 0 citations
Primary and metastatic brain tumors remain among the most challenging malignancies to treat, with limited therapeutic options and poor clinical outcomes despite substantial advances in cancer immunotherapy. Although immune checkpoint blockade (ICB) and other immunotherapies have transformed the treatment landscape for...
Riley G. Young, Arden O. Edgerton, Kaylyn A. Clouser et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.